Canada has become the first G7 nation to approve generic versions of semaglutide — the active ingredient in the blockbuster weight-loss and diabetes drugs Ozempic and Wegovy — and pharmacies across the country have begun stocking the lower-cost alternatives this month. The development has prompted renewed scrutiny of why American patients, who first drove global demand for these medications, remain unable to access cheaper versions.
What Canada Has Approved
Health Canada, the country’s federal regulatory agency, cleared several generic semaglutide formulations after determining they are bioequivalent to branded versions produced by Danish pharmaceutical giant Novo Nordisk. The generics are expected to cost significantly less than Ozempic and Wegovy, which have carried price tags of over CAD $300 per month in Canada — and more than $900 per month in the United States without insurance.
Demand for GLP-1 receptor agonists — the drug class that includes semaglutide — has surged dramatically since clinical trials confirmed their effectiveness not only for managing type 2 diabetes but also for achieving meaningful, sustained weight loss.
Why the US Is Lagging
The answer lies primarily in patent law and the US Food and Drug Administration’s approval process. Novo Nordisk holds multiple active patents on semaglutide in the United States that are not set to expire for several more years. Until those patents lapse, generic manufacturers are legally barred from producing competing versions for the American market, regardless of their safety or efficacy.
Canada’s patent landscape differs in key respects, having allowed earlier generic filings to proceed under its regulatory framework. This is not the first time Canada has made lower-cost versions of high-demand medications available before the United States — a pattern that has long frustrated American patient advocates and lawmakers on both sides of the aisle.
Compounding as a Stopgap
In the United States, compounding pharmacies have been legally permitted to produce copies of semaglutide during periods when the drug appeared on the FDA’s official shortage list. That practice came under scrutiny as Novo Nordisk worked to resolve supply constraints, with the FDA moving at various points to restrict compounded versions as shortages eased.
Compounded semaglutide has been substantially cheaper than branded drugs, but quality and dosing consistency concerns have led many physicians to urge caution. The FDA has also warned consumers about unapproved versions circulating online.
What Patients and Advocates Are Saying
For American patients managing obesity or type 2 diabetes, the news from Canada is both encouraging and frustrating. Patient advocacy groups have called on Congress to reform drug patent rules, while some lawmakers have renewed calls for legislation allowing Americans to import approved drugs from Canada. Novo Nordisk has defended its pricing structure and highlighted patient assistance programs for lower-income Americans. How long it will take for affordable generic semaglutide to reach US pharmacies remains uncertain, but Canada’s precedent has added fresh urgency to the debate.
